About 5 results found for searched term "BMX-IN-1" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14880 | BMX-IN-1 | BTK |
| BMX kinase inhibitor | ||
| BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. | ||
| M6804 | IBMX | PDE |
| IMX; Isobutylmethylxanthine; Methylisobutylxanthine; NSC165960; SC2964; 3-isobutyl-1-methylxanthine | ||
| IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. | ||
| M11431 | Poseltinib | BTK |
| HM71224; LY3337641 | ||
| Poseltinib is an orally active, selective, irreversible small-molecule Bruton tyrosine kinase (BTK) inhibitor with an IC50 of 1.95 nM and 0.3, 2.3, and 2.4 fold selective action against BMX, TEC, and TXK, respectively. Poseltinib covalently binds to the active site of BTK (cysteine 481 residue) and effectively inhibits B cell receptor (BCR), Fc receptor (FcR), and Toll-like receptor (TLR) mediated signaling. | ||
| M28664 | PF-06250112 | BTK |
| PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively. | ||
| M28901 | CHMFL-BMX-078 | BTK |
| CHMFL-BMX 078 | ||
| CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
